Skip to main content
. Author manuscript; available in PMC: 2024 May 1.
Published in final edited form as: AJR Am J Roentgenol. 2022 Nov 2;220(5):619–629. doi: 10.2214/AJR.22.28237

Fig. 3—

Fig. 3—

Schematic shows current therapeutic options for patients with advanced prostate cancer, indicating potential role of PSMA radioligand therapy. PC = prostate cancer, ADT = androgen deprivation therapy, ARSI = androgen receptor signaling inhibitor, MMR = mismatch repair, HR = homologous recombination, ADP = adenosine diphosphate. (Information derived from [72].)